The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Sign in to access this content
Sign InSynopsys, Inc. (SNPS) reported strong financial results for the first quarter of fiscal year 2026, with revenue reaching $2.409 billion. This performance hit the high end of the company's prior guidance, reflecting robust execution across its business segments. Non-GAAP earnings per diluted share came in at $3.77, successfully exceeding analyst expectations. In a significant move to return value to shareholders, the board of directors approved a new stock repurchase program authorized for up to $2.0 billion. This buyback reflects management's confidence in the company's long-term cash flow generation and growth prospects. Meanwhile, Kewaunee Scientific (KEQU) announced it will release its third-quarter results on March 11, 2026.